-+ 0.00%
-+ 0.00%
-+ 0.00%

INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis

Benzinga·11/18/2026 13:08:20
Listen to the news
  • VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
  • Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe